Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Downregulation of B7-H4 contributes to the synergistic effect of USP2a-targeted/anti-PD-1 combination therapy in EGFR mutant lung cancer.

Cancer immunology, immunotherapy : CII - 26 Mar 2026

Sun Boshu, Kong Miao, Jiang Xiaorui, Zhu Liang, Zhang Jie, Tan Li, Wang Can, Yuan Zhenyang, Chen Shaomu, Wang Chao, Jiang Ying, Zhang Liang

Abstract excerpt

Anti-PD-1 treatment has shown clinical benefit in malignant cancers. However, EGFR-mutant (EGFR-MT) lung adenocarcinoma, an immune-cold tumor, shows poor response to this immunotherapy. This scenario is associated with elevated levels of B7-H4, an immune checkpoint demonstrating CD8+ T cell inhibition activity. Our previous study has revealed that deubiquitinase USP2a could stabilize B7-H4 protein. Therefore, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Down-Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Immune Checkpoint Inhibitors

Share to Mice, Nude

Share to Programmed Cell Death 1 Receptor

Share to Tumor Microenvironment

Share to Ubiquitin Thiolesterase

Source

Open in PubMed Open full text

Identifiers

PMID: 41885940
DOI: 10.1007/s00262-026-04321-2
PMCID: PMC13022231

Genes

EGFR
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Downregulation of B7-H4 contributes to the synergistic effect of USP2a-targeted/anti-PD-1 combination therapy in EGFR mutant lung cancer.PMID 41885940Read ↗

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.Semantic proximity Read ↗

FBXO28 promotes the malignancy of non-small cell lung cancer through ubiquitination-mediated activation of BRD4Semantic proximity Read ↗

Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.Semantic proximity Read ↗

USP14 Positively Modulates Head and Neck Squamous Carcinoma Tumorigenesis and Potentiates Heat Shock Pathway through HSF1 StabilizationSemantic proximity Read ↗

RNF125 Modulates Tumor Immunity by Promoting Ubiquitination of PD-L1Semantic proximity Read ↗

Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradationSemantic proximity Read ↗

USP14 Inhibition Regulates Tumorigenesis by Inducing Autophagy in Lung Cancer In VitroSemantic proximity Read ↗

USP28 deletion and small molecule inhibition destabilises c-Myc and elicits regression of squamous cell lung carcinomaSemantic proximity Read ↗

Loss of H2B monoubiquitination is associated with poor‐differentiation and enhanced malignancy of lung adenocarcinomaSemantic proximity Read ↗

Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.